As of June 21, 2025, Elite Pharmaceuticals Inc (ELTP) reports a Net Margin of 35.51%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Elite Pharmaceuticals Inc's Net Margin
Over recent years, Elite Pharmaceuticals Inc's Net Margin has shown significant volatility. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-03-31 | 35.51% |
| 2023-03-31 | 10.43% |
| 2022-03-31 | 24.92% |
| 2021-03-31 | 20.05% |
| 2020-03-31 | -12.45% |
This slight upward trend highlights how Elite Pharmaceuticals Inc manages its overall profitability and cost control over time.
Comparing Elite Pharmaceuticals Inc's Net Margin to Peers
To better understand Elite Pharmaceuticals Inc's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Elite Pharmaceuticals Inc (ELTP) | 35.51% |
| Viaderma Inc (VDRM) | 14.05% |
| Opiant Pharmaceuticals Inc (OPNT) | 6.30% |
| Crescita Therapeutics Inc (CTX.TO) | -14.04% |
| Avicanna Inc (AVCN.TO) | -14.21% |
| NovaBay Pharmaceuticals Inc (NBY) | -73.85% |
Compared to its competitors, Elite Pharmaceuticals Inc's Net Margin is higher than all peers, suggesting strong overall cost management and pricing power.